Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XNW 5004

Next Previous
X
Search
Drug Profile

XNW 5004

Alternative Names: XNW-5004

Latest Information Update: 04 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evopoint Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Haematological malignancies
  • Phase I/II Lymphoma; Solid tumours
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Apr 2023 Phase-II clinical trials in Haematological malignancies in China (PO), prior to April 2023 (Evopoint Biosciences pipeline, June 2023)
  • 14 Apr 2023 Pharmacodynamics, pharmacokinetics and safety data from preclinical trials in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 06 Apr 2023 Evopoint Biosciences and Merck & Co enter into a clinical trial collaboration agreement for XNW 5004 in Solid tumours (Combination therapy, Late-stage disease)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top